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Abstract
All UDP-glucuronosyltransferase enzymes (UGTs) share a common cofactor, UDP-glucuronic acid
(UDP-GlcUA). The binding site for UDP-GlcUA is localized to the C-terminal domain of UGTs on
the basis of amino acid sequence homology analysis and crystal structures of glycosyltransferases,
including the C-terminal domain of human UGT2B7. We hypothesized that the 393DQMD-
NAK399 region of human UGT1A10 interacts with the glucuronic acid moiety of UDP-GlcUA. Using
site-directed mutagenesis and enzymatic analysis, we demonstrated that the D393A mutation
abolished the glucuronidation activity of UGT1A10 toward all substrates. The effects of the alanine
mutation at Q394, D396, and K399 on glucuronidation activities were substrate-dependent. Previously,
we examined the importance of these residues in UGT2B7. Although D393 (D398 in UGT2B7) is
similarly critical for UDP-GlcUA binding in both enzymes, the effects of Q394 (Q399 in UGT2B7)
to Ala mutation on activity were significant but different between UGT1A10 and UGT2B7. A model
of the UDP-GlcUA binding site suggests that the contribution of other residues to cosubstrate binding
may explain these differences between UGT1A10 and UGT2B7. We thus postulate that D393 is
critical for the binding of glucuronic acid and that proximal residues, e.g., Q394 (Q399 in UGT2B7),
play a subtle role in cosubstrate binding in UGT1A10 and UGT2B7. Hence, this study provides
important new information needed for the identification and understanding of the binding sites of
UGTs, a major step forward in elucidating their molecular mechanism.
UGTs metabolize many endogenous and exogenous compounds, such as bilirubin, steroids,
fatty acids, bile acids, retinoids, drugs, and environmental pollutants, and, in fact, dominate
phase II detoxification pathways. UGTs are highly promiscuous, catalyzing the transfer of
glucuronic acid (GlcUA) from UDP-GlcUA to lipophilic substrates. The genes encoding UGTs
have been assigned to two families on the basis of sequence similarities (Mackenzie et al.,
1997). UGT1A isoenzymes are derived from a single gene locus; the 13 first exons encoding
the N-terminal domain are unique to each isoenzyme, whereas exons 2 to 5 encoding the C-
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terminal domain are identical in all UGT1As (Owens and Ritter, 1992; Mackenzie et al.,
1997).
UGTs belong to the GT1 family of glycosyltransferases. They are predicted to adopt a GT-B
fold, which consists of two separate Rossmann-like domains with a connecting region and a
catalytic site located between them (Breton et al., 2006). The C-terminal domain contains the
cosubstrate binding domain, whereas the N-terminal domain contains the acceptor substrate
binding site.
A full UGT crystal structure is not available. This lack of structural knowledge has resulted in
the prediction of UGT structures using selective inhibitors, amino acid-specific chemical
modification reagents, and amino acid alignments. Site-directed mutagenesis of the amino
acids identified in those studies has been applied to the characterization of UGT binding sites
with the goal of identifying critical amino acids within the binding sites (Mackenzie, 1990;
Moehs et al., 1997; Senay et al., 1997; Radominska-Pandya et al., 1999; Ouzzine et al.,
2000; Senay et al., 2002; Coffman et al., 2003).
Recently, progress has been made in identifying the amino acids in both the substrate and
cosubstrate binding sites. Miley et al. (2007) published the 1.8-Å resolution apo crystal
structure of the C-terminal domain of human UGT2B7 (2B7CT), which binds UDP-GlcUA.
Comparisons of this structure with those for other members of the GT-B superfamily showed
that UGT2B7 possessed a nucleotide-sugar binding site most similar to those found in the
related plant flavonoid glucosyltransferases. A model of UDP-GlcUA binding to 2B7CT was
used to design point mutations that would interfere with binding to different regions of UDP-
GlcUA. Mutations to residues predicted to interact with the diphosphate and glucuronic acid
moieties of UDP-GlcUA preferentially abolished activity, whereas mutations to residues
predicted to interact with the uracil group only moderately reduced activity. In a separate study,
the highly conserved His371 residue within the C-terminal domain of UGT1A6 was predicted
to play a role in catalysis (Ouzzine et al., 2003) but was later shown to be involved in binding
UDP-GlcUA along with the highly conserved Glu379 (Patana et al., 2007).
In the work reported here, we have used site-directed mutagenesis, modeling, and kinetic
analyses to identify which amino acids in UGT1A10 are critical for UDP-GlcUA binding. We
hypothesized that the 393DQMDNAK399 amino acid sequence of UGT1A10 is the best
candidate for interaction with the glucuronic acid moiety of UDP-GlcUA. We present data
confirming that the DQxD motif in UGT1A10 is critical for activity. Furthermore, comparison
of these results with those of similar studies we conducted with UGT2B7 suggests that there
may be subtle differences between the tertiary structures and/or functions of the C-terminal
domains of UGT2B7 and UGT1A10 and possibly between the 1A and 2B families as a whole.
Materials and Methods
Materials
[14C]4-Nitrophenol (pNP, 6.4 mCi/mmol), saccharolactone (saccharic acid-1,4-lactone), UDP-
GlcUA, and horseradish peroxidase- conjugated mouse anti-rabbit IgG were purchased from
Sigma-Aldrich (St. Louis, MO). [14C]UDP-GlcUA (325 mCi/mmol) was purchased from
PerkinElmer Life and Analytical Sciences (Boston, MA). The His Hi-trap columns and ECL
Western blotting detection system were from GE Healthcare (Piscataway, NJ). Anti-UGT1A
antibody was from BD Biosciences Gentest (San Jose, CA) and the anti-tetraHis antibody was
from QIAGEN (Valencia, CA). All other chemicals and solvents were of analytical grade.
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Cloning and Expression of Human Recombinant His-Tagged UGTs
Details of the cloning and expression of UGT1A10 in baculovirus-infected Sf9 insect cells as
His-tagged proteins and the preparation of enriched membrane fractions have been reported
previously (Kurkela et al., 2003; Kuuranne et al., 2003). The same is true for human UGT2B7
cloning and expression (Miley et al., 2007)
Site-Directed Mutagenesis and Expression of Mutated Recombinant Proteins
Wild-type UGT1A10 DNA was subcloned between the BamHI and HindIII site of plasmid
pcDNA3.1(+) (Invitrogen, Carlsbad, CA) to generate pcDNA-UGT1A10 for use as a template
for site-directed mutagenesis. Site-directed mutagenesis was performed using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer’s
instructions. The mutagenic primers used, with the mutated nucleotides underlined, were
D393A-for 5′-GCCCTTGTTTGGTGCCCAGATGGACAATG-3′, Q394A-for 5′-
CCTTGTTTGGTGATGCGATGGACAATGCAAAGC-3′, D396A-for 5′-
GGTGATCAGATGGCCAATGCAAAGCGC-3′, and K399A-for 5′-
CAGATGGACAATGCAGCGCGCATGGAGAC-3′.
These oligonucleotides and their reverse complement primer pairs were used in each reaction,
and each mutagenesis was verified by DNA sequencing. Subsequently, new recombinant
baculovirus was generated using the Bac-to-Bac system (Invitrogen), followed by the
production of the mutant proteins in insect cells as described previously (Kurkela et al.,
2003). Wild-type and mutant protein expression levels were determined by Western blot
analysis using anti-UGT1A and anti-tetraHis antibodies, and the protein levels were
standardized as described previously (Luukkanen et al., 2005). The details of human UGT 2B7
mutant protein expression have been reported previously (Miley et al., 2007)
Enzymatic Assays and Kinetic Analyses
We measured glucuronidation of pNP, 2-hydroxyestrone (2-OH-E1), tetrachlorocatechol
(TCC), chrysin, and genistein for UGT1A10 and glucuronidation of androsterone,
hyodeoxycholic acid, and TCC for UGT2B7 as described previously (Senay et al., 1999).
Briefly, we used membrane protein from wild-type UGT1A10 and the D393A, Q294A,
D396A, and K399A mutants and wild-type UGT2B7 and the D398A and Q399A mutants. The
protein was incubated in 100 μM Tris-HCl (pH 7.4)-5 mM for MgCl2-5 mM saccharolactone
with each substrate (750 μM, for screening) in a total volume of 30 μl. The reactions were
started by adding 4 mM of either unlabeled or [14C]UDP-GlcUA and incubated at 37°C for 20
min.
Apparent kinetic values for each UGT1A10-based enzyme toward both the substrate and
cosubstrate were analyzed. To determine the Km and Vmax values for these enzymes toward
pNP, we added 100 to 4000 μM [14C]pNP, started the reactions by adding 4 mM UDP-GlcUA,
and then incubated them at 37°C for 20 min in a total volume of 30 μl. To determine the Km
and Vmax values for these enzymes toward UDP-GlcUA, we used 100 to 5000 μM UDP-GlcUA,
started the reactions by adding 1 mM [14C]pNP, and incubated them at 37°C for 20 min in a
total volume of 30 μl.
For each assay, the reactions were stopped by adding 30 μl of ethanol. Aliquots (40 μl) of each
sample were then applied to the preabsorbent layer of channeled silica gel thin-layer
chromatography (TLC) plates [Baker 250Si-PA (19C), VWR Scientific, Sugarland, TX], and
glucuronidated products and unreacted substrates were separated by development in
chloroform-methanol-glacial acetic acid-water (65:25:2:4, v/v).
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Radioactive compounds were localized on TLC plates by autoradiography for 3 to 4 days at
−80°C. Silica gel in areas corresponding to the glucuronide bands identified from
autoradiograms and the corresponding areas from control lanes were scraped from the TLC
plates into scintillation vials, and radioactivity was measured using a Perkin-Elmer liquid
scintillation counter (Packard Tri-Carb 2100TR). The results of these experiments were
analyzed and apparent kinetic parameters were determined using Prism 4 software (GraphPad
Software Inc., San Diego, CA).
Homology Modeling
A model of part of the C-terminal domain of UGT1A10, residues 280 to 441, was built using
the Homology module in the Insight II program (version 2005; Accelrys, San Diego, CA). The
structure of the corresponding domain in UGT2B7 (2O6L) was used as the template. The
sequences were aligned using EMBOSS pairwise alignment algorithms
(http://www.ebi.ac.uk/emboss/align/). The model was minimized in the Insight II Discover
module using the Amber force field. Steepest descent was used, followed by conjugate gradient
minimization until 0.001 root mean square energy gradient was achieved. The quality of the
model was verified by Procheck v3.5.4. The cosubstrate UDP-GlcUA was manually docked
into the partial model of UGT1A10 in the same conformation as UDP-glucose in the plant
flavonoid glucosyltransferase (VvGT1) structure (Offen et al., 2006). The enzyme-UDP-
GlcUA complex was further minimized using the Amber force field as well as steepest descent
and conjugate gradient minimizations.
Results
Site-Directed Mutagenesis of UGT1A10
Several amino acids in the 393DQMDNAK399 region of UGT1A10 are thought to be involved
with UDP-GlcUA binding. Structural data suggested that D393 and Q394 make direct contact
with the glucuronic acid moiety of UDP-GlcUA. In addition, D396 is highly conserved among
UGT enzymes, although it is not predicted to interact directly with the UDP-GlcUA
cosubstrate. Lastly, the solvent-exposed K399 residue could play a secondary role in ligand
binding. To begin to assess the roles of these residues, we constructed four recombinant
UGT1A10 mutants: D393A, Q394A, D396A, and K399A. Wild-type and mutant protein
expression levels were determined by Western blot analysis using anti-UGT1A and anti-
tetraHis antibodies, and all proteins were expressed in sufficient amounts (data not shown).
Analysis of Recombinant Protein Activity
Wild-type UGT1A10, D393A, Q394A, D396A, and K399A were assayed for activity toward
several prototypical UGT1A10 substrates, and the glucuronidation products were separated by
TLC (Fig. 1). Replacing D393 with alanine totally abolished the activity of this protein toward
all of the substrates under investigation. However, the other three mutants, Q394A, D396A,
and K399A, were all partially active. They all showed wild-type activity with TCC as a
substrate but varying activity with all of the other substrates (Fig. 1). D396A was much less
active with pNP and 2-OH-E1 but showed wild-type activity with the flavonoid substrates,
chrysin and genistein. There was a significant decrease in the activity of Q394A toward these
four substrates, with nearly complete inactivity toward pNP. K399A showed no change in
activity toward pNP or 2-OH-E1 compared with the wild type, but it was significantly less
active with genistein, and, interestingly, significantly more active with chrysin.
Kinetic Analysis of Wild-Type UGT1A10 and Mutant Enzymes toward pNP and UDP-GlcUA
The apparent kinetic parameters for the D393A and Q394A mutants with pNP could not be
calculated because they were inactive toward this substrate. For D396A with pNP as substrate,
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the Km (pNP) value was unchanged from that of the wild type, but the Vmax (pNP) decreased
approximately 3-fold (Table 1; Fig. 2). The K399A mutant kinetics changed more with pNP,
i.e., the apparent Km (pNP) and Vmax (pNP) values increased ~3- and 5-fold, respectively.
We determined the kinetic parameters toward UDP-GlcUA for wild-type UGT1A10 and
mutants D396A and K399A at constant pNP concentrations (Table 1; Fig. 2). The
Km (UDP-GlcUA) values for both D396A and K399A increased approximately 1.5-fold compared
with the wild type. However, the Vmax (UDP-GlcUA) value for D396A was essentially unchanged,
whereas the Vmax (UDP-GlcUA) increased 3-fold.
Comparison of the Effects of the D393A and Q394A Mutations on UGT1A10 and UGT2B7
Activity
Figure 3 juxtaposes the effect of D393A and Q394A on UGT1A10 activity to the effect of the
corresponding mutations, D398A and Q399A, on UGT2B7 glucuronidation of typical
UGT1A10 and UGT2B7 substrates. The Asp→Ala mutation totally abolished the catalytic
activity in UGT1A10 and severely impaired the activity in UGT2B7, but the Gln→Ala
mutation affected the two isoenzymes differently. In UGT2B7, the Q399A mutation resulted
in total loss of activity, whereas in UGT1A10, the effect was substrate-dependent; only activity
toward pNP was abolished.
Homology Modeling
To shed new light on UDP-GlcUA binding in general and on the apparent differences between
UGT1A10 and UGT2B7 in particular, a model of UDP-GlcUA bound to UGT1A10 and
UGT2B7 (Fig. 4) was built. The structure of the UDP-GlcUA binding fragment of UGT2B7
(Miley et al., 2007) was used as a template to generate a model of the C-terminal domain of
UGT1A10. However, because the UGT2B7 structure does not have cosubstrate bound, we
manually docked UDP-GlcUA to the UGT1A10 partial model in the same conformation as
UDP-glucose in VvGT1 (Offen et al., 2006). The docking shows how H369, E378, D393, and
Q394 (UGT1A10 numbering) are arranged around the UDP-GlcUA. All of these residues have
been implicated in UDP-GlcUA binding in UGT1A10 (this study), UGT2B7 (Miley et al.,
2007), or UGT1A6 (Patana et al., 2007). Furthermore, S372 and H373 (UGT1A10 numbering)
also appear to be important on the basis of the docked model. These two residues, which are
not identical in all UGTs (Figs. 4 and 5), can hydrogen bond to the UDP-GlcUA; the changes
at these residues may thus explain some of the differences in UDP-GlcUA binding between
UGT1A10 and UGT2B7, as S372 is replaced by Ala and H373 by Asn in UGT2B7, respectively.
Discussion
The present studies were undertaken to clarify the role of D393, Q394, D396, and K399 in the
binding of UDP-GlcUA and the catalytic activity of UGT1A10. Of the four mutated residues,
D393 is apparently essential for binding UDP-GlcUA because of the complete loss of activity
in the D393A mutant. In contrast, D396 plays a minor role in substrate turnover, but the 1.5-
fold decrease in Km (UDP-GlcUA) indicates a weaker association for the cosubstrate. This
alteration in cosubstrate binding compromises pNP turnover, as shown by a 3-fold decrease in
Vmax (pNP) without any change Km (pNP).
The conserved K399 also might have a role in cosubstrate binding. Surprisingly, the K399A
mutant led to significant reorganization of the Michaelis complex; there were changes in
Vmax and Km for both substrate and cofactor. Even though Km (pNP) increased 3-fold,
Vmax (pNP) increased 5-fold, leading to an almost 2-fold increase in efficiency as measured by
Vmax/Km. Similarly, Km (UDP-GlcUA) increased 1.5-fold, whereas Vmax (UDP-GlcUA) increased
3-fold, with the net effect being a 2-fold increase in catalytic efficiency. Although the effect
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on Km suggests changes in recognition of substrate and cosubstrate, the effect on Vmax supports
changes in the rate-limiting step(s) that depend on interactions with both molecules.
Although the molecular details of the catalytic cycle are not known for this reaction, we
speculate that K399 coordinates substrate and cofactor indirectly to form the Michaelis complex
and may also be involved with releasing coupled product. Because the coupled product contains
both substrate and most of the cofactor, weaker binding of the individual molecules would be
additive, and the mutant would bind product more weakly than the wild type. If product release
is rate-limiting, the increase in Vmax may be due to decreased affinity of the mutant for product.
Taken together, these studies suggest that K399 plays a role in coordinating interactions between
substrate and cofactor to elicit catalytic turnover. The higher efficiency of the mutant reflects
the ability to saturate the enzyme to maximize turnover. However, within a cell, the high Km
values for substrate and cofactor may preclude saturation of the enzyme, leading to less efficient
turnover. Further analysis of the catalytic role of K399 is clearly warranted.
The novelty of the role of D393 in UGT1A10 activity has broader implications because of the
conservation of this residue in all human UGTs (Fig. 5). Comparison of the apo structure of
the C-terminal domain of human UGT2B7 (2B7CT) (Miley et al., 2007) with those of VvGT1
and UGT71G1 from the plant Medicago truncatula revealed a high level of structural
homology despite their low sequence identity (~19%). Because 2B7CT only crystallized in the
absence of UDP-GlcUA, it was modeled into the 2B7CT structure using the structure of
VvGT1 as a guide. On the basis of this model, the residues of UDP-GlcUA binding were
classified into three groups: residues predicted to interact with the glucuronic acid, uracil base,
and diphosphate moieties, respectively (Fig. 6). A panel of point mutations at those positions
was generated, and their impact on UGT2B7 enzyme activity was investigated (Miley et al.,
2007).
The analysis of UGT2B7 motif substitutions demonstrates changes in catalytic parameters
similar to those observed for UGT1A10 (Fig. 3) (Miley et al., 2007). The UGT2B7 residues
targeted in that study (D398 and Q399) correspond to D393 and Q394 in the DQxDxxK motif in
UGT1A10. An alanine at either of these positions severely compromises enzyme activity
(Miley et al., 2007), although the specific effects on the kinetic parameters were not determined.
An important difference between these UGTs is the magnitude of the effects on the respective
enzymatic activities. Although the D393A UGT1A10 mutant is completely inactive, the
D398A UGT2B7 mutant retains residual activity. Conversely, the Q394A UGT1A10 mutant
retains activity, although with significant variability depending on substrate; the corresponding
Q399A UGT2B7 mutant is inactive. There might therefore be differences between the tertiary
structures and functions of the C-terminal domains of UGT2B7 and UGT1A10 and possibly
between the UGT1A and UGT2B families as a whole. This difference is not surprising when
the relatively low amino acid sequence homology between these enzymes in this region (51%
in the region shown in Fig. 5) is taken into account.
Why should the D→A and Q→A substitutions have different effects in UGT1A10 and
UGT2B7 even though the motif is conserved? We explain this observation through our
homology model of the UDP-GlcUA binding site for UGT1A10 based on the UGT2B7 partial
structure. In the superimposed structures, not only do D393 and Q394 (UGT1A10 numbering)
occupy approximately the same position but also the UGT1A10/UGT2B7 residues H369/
H374, E377/E382, D393/ D398, and Q394/Q399 adopt similar positions in the binding site.
Nevertheless, the structures display different hydrogen bonding patterns. At the bottom of the
binding site in Fig. 4, UGT1A10 and UGT2B7 do not use the same residues to coordinate
UDP-GlcUA. Specifically, UGT1A10 uses S372 and H373 for binding, whereas UGT2B7 uses
A377 and N378. Hydrogen bonding between S372 and the sugar moiety of UDP-GlcUA in
UGT1A10 is not possible for UGT2B7. This change may explain the more severe effect of the
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Glu→Ala substitution in UGT2B7 compared with that of UGT1A10. The Q394A mutant of
UGT1A10 may retain partial activity because of the stabilizing hydrogen bond through S372.
The presence of H373 (N378 in UGT2B7) may also induce a less obvious effect on substrate
turnover. The other two residues of UGT1A10 studied, D396 and K399, do not appear to interact
with the cosubstrate directly.
In summary, these results suggest that UDP-GlcUA interacts with D393 and that mutation of
this amino acid results in the total loss of enzyme activity. In addition, the identification of this
specific amino acid as having a critical role in UDP-GlcUA binding can be extrapolated to all
UGTs, as evidenced by crystal structure data (Miley et al., 2007). In the future, this knowledge
could be exploited for the design of UDP-GlcUA analogs of clinical and pharmacological
importance with the aim of increasing and/or decreasing the biological response of UGTs and/
or eliminating any undesired side effects of glucuronidation.
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Screening of the glucuronidation of pNP, 2-OH-E1, TCC, chrysin, and genistein by
recombinant human UGT1A10 and mutants D396A, Q394A, D393A, and K399A.
Glucuronidation activity was measured using membrane fractions of recombinant wild-type
and mutant UGTs expressed as His-tagged proteins in baculovirus-infected Sf9 insect cells.
Products were separated by TLC and identified by autoradiography as described under
Materials and Methods. The results were analyzed by one-way analysis of variance followed
by a Dunnett’s multiple comparison test. Measurements that vary significantly from the
dimethyl sulfoxide control are indicated. *, p < 0.05; **, p < 0.01; ***, p < 0.001).
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Determination of kinetic parameters for glucuronidation of pNP and binding of UDP-GlcUA
by recombinant UGT1A10 and mutants D393A, Q394A, D393A, and K399A. Assays were
carried out by incubating membrane fractions containing recombinant UGT1A10 (10 μg) or
its mutants (20 μg) with increasing concentrations (shown in the figure) of pNP at a constant
concentration of [14C]UDP-GlcUA (4 mM), or with increasing concentrations (shown in the
figure) of UDP-GlcUA at a constant concentration of [14C]pNP (1 mM) for 20 min at 37°C.
These were used to obtain apparent kinetic parameters with pNP and UDP-GlcUA,
respectively. Reactions were stopped by the addition of ethanol, and products separated by
TLC and identified by autoradiography as described under Materials and Methods. Curve fits
were determined using GraphPad Prism 4 software. The curve fits to the data from each of the
substrates (mean ± S.E.M. of two to four determinations) are shown.
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Comparison of the effects of DQ mutation on UGT1A10 and UGT2B7. Glucuronidation
activity was measured using membrane fractions of recombinant UGTs expressed as His-
tagged proteins in baculo-virus-infected Sf9 insect cells using typical UGT1A10 and UGT2B7
substrates.
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A ball-and- stick representation of the model of the UDP-GlcUA binding site in UGT1A10
(carbon, gray) and UGT2B7 (carbon, green). (In both models: blue, nitrogen; red, oxygen; and
orange, phosphate.) Dashed black lines represent possible hydrogen bonds. A model of the
UDP-GlcUA binding site of UGT1A10 was built using the structure of this domain in UGT2B7
as a template (see Materials and Methods for details). The figure (produced in PyMOL
[http://www.pymol.org]) shows the bound cosubstrate and the location of key residues in either
UGT1A10 or UGT2B7 within the hydrogen-bonding distance. The residue types and
numbering are indicated for both UGT1A10 (black) and UGT2B7 (green).
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Amino acid sequence alignment. Amino acid sequence alignment of UGT1A, UGT2B4,
UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17, 2-hydroxyacylsphingosine 1-β-
galactosyl-transferase (CGT), baculovirus ecdysteroid UDP-glucosyltransferase (BeGT),
Streptomyces lividans macrolide glycosyltransferase (MGT), and Escherichia vulneris
zeaxanthin glucosyltransferase (CRTX). Numbers related to the amino acid sequences are
based on information deposited in GenBank (UGT1A1: AF180372; UGT2B4: NP 066962;
UGT2B7: NP 001065; UGT2B10: NP 001066; UGT2B11: NP 001064; UGT2B15: NP
001067; UGT2B17: NP 001068; CGT: JC5423; BeGT: AAA66785; MGT: ABA28305; and
CRTX: Q01330). *, numbering is based on UGT1A1 (for UGT1A3, 1A4, and 1A5, add 1; for
UGT1A6 subtract 1; for UGT1A7, 1A8, 1A9, and 1A10 subtract 2). ■, amino acids conserved
in all aligned enzymes; ♦, amino acids conserved in all but one aligned enzyme.
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UDP-GlcUA moieties. The structure of UDP-GlcUA contains glucuronic acid (A),
diphosphate (B), and nucleic acid moieties (C), all of which could interact with amino acids
in the UGT structure.
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